The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition - PubMed (original) (raw)
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition
Xiaofeng Jiang et al. Clin Cancer Res. 2013.
Abstract
Purpose: Selective BRAF inhibition (BRAFi) provides a paradigm shift for melanoma treatment. The duration of benefit is typically limited before resistance develops. Interest remains in combining targeted and immune therapies to overcome resistance and improve durability of clinical benefit. One mechanism of evading immune destruction is programmed death-1-ligand 1 (PD-L1) expression by tumors that results in potent antitumor immune suppression.
Experimental design: BRAFi-resistant melanoma cells were examined for changes in PD-L1 expression by immunoblot and flow cytometry. Signaling pathways involved in altering PD-L1 expression were examined. Strategies to maximize the effect of the BRAFi therapy were studied including MEKi, MEKi combinations, and additional pathways including phosphoinositide-3 kinase (PI3K).
Results: Melanoma cells resistant to BRAFi exhibit increased MAPK signaling and promotion of PD-L1 expression. PD-L1 expression is transcriptionally modulated by c-Jun and augmented by STAT3. MEK inhibition (MEKi) regains downregulation of MAPK signaling and suppresses the production of PD-L1. MEKi in melanoma cells shows dual therapeutic effects with simultaneous suppression of PD-L1 expression and induction of apoptosis. By combining MEKi with BRAFi, an additive effect on the inhibition of PD-L1 expression results.
Conclusions: We report a novel mechanism that suppresses preexisting immune responses in patients with melanoma receiving BRAFi therapy. BRAFi resistance leads to increased expression of PD-L1 in melanoma cells, mediated by c-Jun and STAT3. MEKi may be feasible to counteract BRAFi resistance of MAPK reactivation and also for the additive effect of PD-L1 suppression. Potential therapeutic benefits of combining targeted inhibitors and immune modulation to improve patient outcomes should be investigated.
Comment in
- A focus on PD-L1 in human melanoma.
Hersey P, Gallagher S. Hersey P, et al. Clin Cancer Res. 2013 Feb 1;19(3):514-6. doi: 10.1158/1078-0432.CCR-12-3312. Epub 2012 Dec 18. Clin Cancer Res. 2013. PMID: 23251000
Similar articles
- ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Ojha R, Leli NM, Onorati A, Piao S, Verginadis II, Tameire F, Rebecca VW, Chude CI, Murugan S, Fennelly C, Noguera-Ortega E, Chu CT, Liu S, Xu X, Krepler C, Xiao M, Xu W, Wei Z, Frederick DT, Boland G, Mitchell TC, Karakousis GC, Schuchter LM, Flaherty KT, Zhang G, Herlyn M, Koumenis C, Amaravadi RK. Ojha R, et al. Cancer Discov. 2019 Mar;9(3):396-415. doi: 10.1158/2159-8290.CD-18-0348. Epub 2018 Dec 18. Cancer Discov. 2019. PMID: 30563872 Free PMC article. - ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
Alves-Fernandes DK, Oliveira ÉA, Faião-Flores F, Alicea-Rebecca G, Weeraratna AT, Smalley KSM, Barros SBM, Maria-Engler SS. Alves-Fernandes DK, et al. Pharmacol Res. 2019 Mar;141:63-72. doi: 10.1016/j.phrs.2018.12.006. Epub 2018 Dec 11. Pharmacol Res. 2019. PMID: 30550954 - PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.
Kakavand H, Wilmott JS, Menzies AM, Vilain R, Haydu LE, Yearley JH, Thompson JF, Kefford RF, Hersey P, Long GV, Scolyer RA. Kakavand H, et al. Clin Cancer Res. 2015 Jul 15;21(14):3140-8. doi: 10.1158/1078-0432.CCR-14-2023. Epub 2015 Jan 21. Clin Cancer Res. 2015. PMID: 25609064 - Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M, Westphal D, Wehner R, Schmitz M, Beissert S, Praetorius C, Meier F. Kuske M, et al. Pharmacol Res. 2018 Oct;136:151-159. doi: 10.1016/j.phrs.2018.08.019. Epub 2018 Aug 23. Pharmacol Res. 2018. PMID: 30145328 Review. - MEK and RAF inhibitors for BRAF-mutated cancers.
Belden S, Flaherty KT. Belden S, et al. Expert Rev Mol Med. 2012 Oct 12;14:e17. doi: 10.1017/erm.2012.11. Expert Rev Mol Med. 2012. PMID: 23058743 Review.
Cited by
- Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
Lelliott EJ, McArthur GA, Oliaro J, Sheppard KE. Lelliott EJ, et al. Front Immunol. 2021 May 7;12:661737. doi: 10.3389/fimmu.2021.661737. eCollection 2021. Front Immunol. 2021. PMID: 34025662 Free PMC article. Review. - BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.
Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P. Liu C, et al. Clin Cancer Res. 2013 Jan 15;19(2):393-403. doi: 10.1158/1078-0432.CCR-12-1626. Epub 2012 Nov 30. Clin Cancer Res. 2013. PMID: 23204132 Free PMC article. - Inhibition of α4β1 Integrin Activity by Small Tellurium Compounds Regulates PD-L1 Expression and Enhances Antitumor Effects.
Chaouat A, Kalechman Y, Hay O, Manoim JE, Lantner T, Niderberg E, Hauschner H, Sredni DK, Cohen T, Schlesinger A, Nadler R, Barda-Saad M, Noy E, Albeck M, Longo DL, Sredni B. Chaouat A, et al. Int J Biol Sci. 2024 Aug 12;20(11):4407-4423. doi: 10.7150/ijbs.95350. eCollection 2024. Int J Biol Sci. 2024. PMID: 39247817 Free PMC article. - MUC3A induces PD-L1 and reduces tyrosine kinase inhibitors effects in EGFR-mutant non-small cell lung cancer.
Luo Y, Ma S, Sun Y, Peng S, Zeng Z, Han L, Li S, Sun W, Xu J, Tian X, Wang F, Wu Q, Xiao Y, Zhang J, Gong Y, Xie C. Luo Y, et al. Int J Biol Sci. 2021 Apr 12;17(7):1671-1681. doi: 10.7150/ijbs.57964. eCollection 2021. Int J Biol Sci. 2021. PMID: 33994852 Free PMC article. - WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function.
Yoon HJ, Kim GC, Oh S, Kim H, Kim YK, Lee Y, Kim MS, Kwon G, Ok YS, Kwon HK, Kim HS. Yoon HJ, et al. Exp Mol Med. 2022 Nov;54(11):1913-1926. doi: 10.1038/s12276-022-00876-z. Epub 2022 Nov 10. Exp Mol Med. 2022. PMID: 36357569 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous